FCF’s Second Scientific Summit

FCF is excited to report that collaboration and sharing was the key mantra at the 2017 Summit. The presenters, researchers and physicians, shared both their published and unpublished scientific findings. After each presentation there was time for questions and answers prompting significant discussion.

The wrap-up session was a round-table discussion entitled Roadmap to a Cure. Each group of 8 or so participants, selected randomly, gave FCF feedback on the most important next steps for the Foundation. The to-do list is significant and the Foundation will start working on the strategies and suggestions immediately. All participants left energized and stimulated to continue working on a cure for fibrolamellar. A special thanks to Dr. Ghassan Abou Alfa of Memorial Sloan Kettering who helped the Foundation organize the Summit and served as the moderator.

See below for messages from several researchers from the conference:

Difficulties of working with small patient populations – Dr. John Scott, U of Washington

Immunotherapy and liver cancer – Dr. Tim F. Greten, NIH

Immunology in rare cancers – Jill O’Donnell Tormey, Ph.D., Cancer Research Institute

The following institutions and industry partners (listed alphabetically) were represented at the summit:

Blue Print Medicines
Cancer Research Institute
Casi Pharmaceuticals
Cellaria LLC
Cornell University
Duke University Medical Center
Johns Hopkins School of Medicine
Massachusetts General Hospital/Harvard Medical School
Mayo Clinic
MD Anderson Cancer Center
Memorial Sloan Kettering
National Institute of Health
NORD (National Organization of Rare Disease)
PhoenixSongs Biologicals
Puma Biotechnology
Rare Disease Communications
Seattle Children’s Hospital
St. Jude Childrens Research Hospital
Stanford University
Target Cancer Foundation
The Bili Project Foundation
University of California San Francisco
University of Copenhagen
University of North Carolina School of Medicine
University of Texas Southwestern Medical Center
University of Vermont Cancer Center
University of Washington
University of Wisconsin-Madison